Independent Commissioning Agent (Owner’s Advocate) Services for U.S. Army Medical Research Institute of Infectious Diseases

THIS IS A REQUEST FOR INFORMATION (RFI)/SOURCES SOUGHT (SS) NOTIFICATION INCLUDING INDUSTRY FEEDBACK 1. Title: Independent Commissioning Agent (Owner�s Advocate) Services for U.S. Army Medical Research Institute of Infectious Diseases 2. Contracting Office: Defense Health Agency Contracting Activity (DHACA), R&D Contracting Division 1 - Branch 4 3. Location: Fort Detrick, Frederick, MD 4. Summary: This RFI/SS is issued solely for information and planning purposes and shall not be construed as a solicitation, restrict the Government as to the ultimate acquisition approach, or serve as an obligation on the part of the USAMRDC. In accordance with FAR 15.201(e), responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. Responders are advised that the United States Government will not pay for any information or administrative costs incurred in response to this RFI. All costs associated with responding to this RFI/SS will be solely at the interested responder�s expense. Not responding to this RFI/SS does not preclude participation in any future Request for Proposal, if any is issued. No evaluation letters and/or results will be issued to Responders responding to this RFI/SS. The information resulting from this RFI/SS will determine interest and capabilities available in the marketplace; and will assist in developing acquisition strategy. 5. Background: The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), located at Fort Detrick, Maryland, is the premier lead medical research laboratory for the U.S. Department of War's biological defense research program. Since 1969, USAMRIID has provided leading edge medical capabilities to deter and defend against current and emerging biological threat agents. The Institute is the only laboratory in the Department of Defense equipped to safely study highly hazardous pathogens requiring maximum containment at Biosafety Level 4. USAMRIID has executed its mission...